Coherus Oncology, Inc. (CHRS) Operating margin 2016–2025
Coherus Oncology, Inc. (CHRS) operating margin by fiscal year — reported operating income divided by reported revenue.
-429.5%FY2025 · since FY2016: -61.2% → -429.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -429.5% | +327.1 pp |
| FY2024 | -756.6% | +16960.0 pp |
| FY2023 | -17716.6% | -17594.9 pp |
| FY2022 | -121.7% | -40.9 pp |
| FY2021 | -80.8% | -113.7 pp |
| FY2020 | 32.9% | +2.6 pp |
| FY2019 | 30.3% | — |
| FY2017 | -14918.8% | -14857.6 pp |
| FY2016 | -61.2% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice